- Reaction score
- 83
https://twitter.com/beIgraviacentre/status/923158508475961346
http://crweworld.com/article/news-p...-tofacitinib-for-treating-hair-loss-disorders
Now, in another step towards their goal of having the first Janus Kinase (JAK) inhibitor hair loss treatments ready to release by 2021, the Trustees of Columbia University in the City of New York have been awarded more new patents in America and Japan.
Both are for the JAK inihibitor tofacitinib and were awarded by the United States Patent and Trademark Office on 24th October 2017 and the Japanese Patent Office on 22nd September 2017.
This latest US patent, which was allowed with 66 claims, covers administering tofacitinib topically or as the ‘sole active ingredient’ in order to treat hair loss or induce hair growth. It specifically states that it may be used in relation to Alopecia Areata – an umbrella term for autoimmune alopecia – and Androgenetic Alopecia, which is more commonly known as Male Pattern Baldness in men, and Female Pattern Hair Loss in women.
http://bit.ly/2lgXMAc
http://bit.ly/2lgXMAc
http://crweworld.com/article/news-p...-tofacitinib-for-treating-hair-loss-disorders
Now, in another step towards their goal of having the first Janus Kinase (JAK) inhibitor hair loss treatments ready to release by 2021, the Trustees of Columbia University in the City of New York have been awarded more new patents in America and Japan.
Both are for the JAK inihibitor tofacitinib and were awarded by the United States Patent and Trademark Office on 24th October 2017 and the Japanese Patent Office on 22nd September 2017.
This latest US patent, which was allowed with 66 claims, covers administering tofacitinib topically or as the ‘sole active ingredient’ in order to treat hair loss or induce hair growth. It specifically states that it may be used in relation to Alopecia Areata – an umbrella term for autoimmune alopecia – and Androgenetic Alopecia, which is more commonly known as Male Pattern Baldness in men, and Female Pattern Hair Loss in women.
http://bit.ly/2lgXMAc
http://bit.ly/2lgXMAc
Last edited: